21.85

3.65% 0.77

After Hours: 22.09 0.24 +1.10%

Urogen Pharma Ltd (URGN)

Overview News Price History Option Chain Financials Discussions Forecast

Urogen Pharma Ltd stock is traded at $21.85, with a volume of 536.87K. It is up +3.65% in the last 24 hours and down -5.12% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Previous Close:

$21.08

Open:

$20.91

24h Volume:

536.87K

Relative Volume:

0.57

Market Cap:

$1.02B

Revenue:

$82.71M

Net Income/Loss:

$-102.24M

P/E Ratio:

-5.9537

EPS:

-3.67

Net Cash Flow:

$-76.57M

1W Performance:

+13.04%

1M Performance:

-5.12%

6M Performance:

+15.30%

1Y Performance:

+108.49%

1-Day Range:

$20.75

$21.89

1-Week Range:

$18.13

$21.89

52-Week Range:

$3.42

$30.00

Urogen Pharma Ltd Stock (URGN) Company Profile

Name

Urogen Pharma Ltd

Sector

Healthcare (1113)

Industry

Biotechnology (624)

Phone

972 9 770 7601

Address

9 HA'TA'ASIYA ST, RA'ANANA

Employee

253

Twitter

@UroGenPharma

Next Earnings Date

2025-03-10

Latest SEC Filings

URGN's Discussions on Twitter

Compare URGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
URGN Urogen Pharma Ltd	21.85	986.73M	82.71M	-102.24M	-76.57M	-3.67
VRTX Vertex Pharmaceuticals Inc	474.17	120.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	771.25	80.15B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	864.42	51.56B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	354.75	47.74B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	336.16	37.38B	4.98B	69.59M	525.67M	0.5197

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-19-25	Initiated	Piper Sandler	Overweight
Jun-16-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-22-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-16-25	Initiated	Scotiabank	Sector Outperform
Feb-19-25	Resumed	Ladenburg Thalmann	Buy
Aug-22-24	Initiated	Guggenheim	Buy
Feb-08-23	Downgrade	Jefferies	Buy → Hold
Apr-27-22	Initiated	Berenberg	Buy
Apr-16-20	Reiterated	H.C. Wainwright	Buy
Apr-13-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	National Securities	Neutral
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy
Nov-15-17	Reiterated	Oppenheimer	Outperform
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Urogen Pharma Ltd Stock (URGN) Latest News

Jan 25, 2026

Bull Run: Can UroGen Pharma Ltd deliver consistent dividendsJuly 2025 Spike Watch & Detailed Earnings Play Alerts - baoquankhu1.vn

Jan 25, 2026

Responsive Playbooks and the URGN Inflection - Stock Traders Daily

Jan 25, 2026

Jan 23, 2026

Dividend Watch: Is now the right time to enter UroGen Pharma LtdJuly 2025 Setups & Growth Oriented Trading Recommendations - baoquankhu1.vn

Jan 23, 2026